9 results
8-K
EX-99.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
are confident that we can accomplish this mission while being disciplined in our decision-making and responsible in our capital allocation,” said Mina
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
that cascade from the strategic milestones represent Company achievements that the Board and Compensation Committee believe further the Company’s mission
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
focus. Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer
8-K
EX-99.1
SLRN
Acelyrin Inc
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
has been productive and rewarding as we marked a number of clinical and corporate milestones supporting our mission to identify, acquire
8-K
EX-99.1
SLRN
Acelyrin Inc
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
achievements.
“The past several months have been transformative for ACELYRIN. We continue to work toward our mission to develop clinically meaningful
424B4
ub981v4 80k
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
a8su716e cccgz1b
1 May 23
IPO registration (amended)
6:10am
S-1
vo9q76up12av
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next